A Study of the Natural History of Leukocyte Chemotactic Factor 2 Amyloidosis (ALECT2) Disease
| Status: | Recruiting |
|---|---|
| Conditions: | Hematology |
| Therapuetic Areas: | Hematology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 3/14/2019 |
| Start Date: | January 29, 2019 |
| End Date: | December 2023 |
| Contact: | Alnylam Clinical Trial Information Line |
| Email: | clinicaltrials@alnylam.com |
| Phone: | 1-877-ALNYLAM |
The purpose of this study is to characterize the natural history of leukocyte chemotactic
factor 2 amyloidotic (ALECT2) disease. In this observational study participants with ALECT2
disease will be enrolled. Participants, who have already reached end-stage renal disease
(ESRD), will provide retrospective chart review data and biological specimens at baseline
only. Other participants, in addition to retrospective chart review, will be followed
prospectively.
factor 2 amyloidotic (ALECT2) disease. In this observational study participants with ALECT2
disease will be enrolled. Participants, who have already reached end-stage renal disease
(ESRD), will provide retrospective chart review data and biological specimens at baseline
only. Other participants, in addition to retrospective chart review, will be followed
prospectively.
Inclusion Criteria:
- Males and females, age 18 years or older;
- Renal biopsy-proven diagnosis of ALECT2;
- For patients with kidney disease that could be due to ALECT2, a renal biopsy may be
obtained to confirm ALECT2 diagnosis.
Exclusion Criteria:
- There are no exclusion criteria for this observational study.
We found this trial at
2
sites
